Reference is made to the stock exchange announcement by IDEX Biometrics ASA (the "Company") on 29 May 2026 regarding the completion of a private placement of new shares in the Company with gross proceeds in the amount of approximately NOK 20 million (the "Private Placement") where the Company allocated 2,500,000 new ordinary shares in the Company ("Offer Shares") each at a subscription price of NOK 8.25 per Offer Share (the "Subscription Price").
Reference is further made to the stock exchange announcement made by the Company on 29 May 2026 regarding the settlement of the Private Placement through a share lending agreement entered into between the Company, the Manager and Anders Storbråten, the Executive Chairman of the Company (the “Share Lender”) (the "Share Lending Agreement"). The Share Lender has on 29 May 2026, pursuant to the Share Lending Agreement and pursuant to the conditions for the Private Placement being fulfilled, lent out 2,500,000 ordinary shares in order to facilitate DVP settlement of the Private Placement (the "Share Lending").
Please see the attached form of notification pursuant to the Market Abuse Regulation article 19.
Following the Share Lending, the Share Lender's holding of 8,227,605 ordinary shares in the Company (of which 6,350,937 ordinary shares are held directly, and 1,876,632 shares are held through Pinchcliffe AS), will be reduced to 5,727,605 ordinary shares in the Company, constituting respectively approximately 10,99% and approximately 7,65% of the share capital and votes outstanding in the Company. Consequently, the Share Lender's total registered holding of shares has fallen below the 10% threshold pursuant to section 4-2 (1) of the Norwegian Securities Trading Act. The above calculations have been made based on a total of 74,808,932 outstanding shares in the Company currently registered in the Norwegian Register of Business Enterprises (the "NRBE").
The Share Lending is made solely for settlement purposes. The Offer Shares pertaining to the Private Placement, together with the 4,107,910 ordinary shares issued in connection with the previous private placement in the Company (also facilitated by a share lending agreement with the Share Lender), as announced in the stock exchange announcements made by the Company on 29 April 2026 and 7 May 2026 (the "Prior Private Placement"), have been issued on a separate, unlisted ISIN and will only be tradable on Euronext Oslo Børs following approval and publication of a listing prospectus as approved by the Norwegian Financial Supervisory Authority, expected during Q2 2026. Following such approval and publication of the prospectus, the remaining shares from the Prior Private Placement and the Offer Shares from the Private Placement will be redelivered to the Share Lender. The Share Lending will consequently not reduce the Share Lender's ownership interest in the Company.
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation Article 19 and section 4-2 and section 5-12 of the Norwegian Securities Trading Act.
For more information, please contact:
Anders Storbråten, Executive Chairman
Tel: +47 416 38 582
E-mail: ir@idexbiometrics.com
About IDEX Biometrics ASA
IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our solutions bring convenience, security, peace of mind and seamless user experiences to the world. Built on patented and proprietary sensor technologies, integrated circuit designs, and software, our biometric solutions target card-based applications for payments and digital authentication. As an industry-enabler we partner with leading card manufacturers and technology companies to bring our solutions to market.